Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Vascular disorders – page 4

  • 846 clinical trials
  • 351 recruiting
  • 382 conditions
  • 28 countries

Conditions in this area

382 conditions with trials, the busiest first

Ischaemic stroke52Migraine48Pulmonary arterial hypertension41Systemic scleroderma40Coronary artery disease37Arteriosclerosis32Acute myocardial infarction30Hypertension29Pulmonary hypertension24Acute coronary syndrome21Giant cell arteritis18Paroxysmal nocturnal haemoglobinuria17Peripheral arterial occlusive disease17Septic shock17Cardiovascular disorder16Subarachnoid haemorrhage16Acute respiratory distress syndrome15Atrial fibrillation15Anti-neutrophil cytoplasmic antibody positive vasculitis14Cerebrovascular accident14Pulmonary embolism14Embolism13Myocardial infarction13Diabetic foot12+358

Clinical trials in Vascular disorders

846 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

846 clinical trials

Acute myocardial infarction+1

Recruiting

Bisoprolol in Patients After Myocardial Infarction with Preserved Ejection Fraction During Cardiac Rehabilitation

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bisoprolol
  • Sponsor:UZ Leuven

Multiple system atrophy

Recruiting

Open-Label Extension Study of ATH434-DP2 in Patients with Multiple System Atrophy

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:5,7-DICHLORO-2-((ETHYLAMINO)METHYL)-8-HYDROXY-3-METHYLQUINAZOLIN-4(3H)-ONE METHANESULFONATE

Coronary artery disease+1

Recruiting

Study to evaluate if colchicine reduces inflammation in patients with chronic coronary artery disease

Registered drug
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Colchicine
  • Sponsor:Rigshospitalet

Pulmonary arterial hypertension

Recruiting

A study to evaluate the safety and effectiveness of IKT-001 compared to a placebo in adults with pulmonary arterial hypertension.

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years

Peripheral venous disease

Recruiting

Study to evaluate the efficacy and safety of personalized tissue engineered veins in patients with severe chronic venous insufficiency

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Allogeneic vein tissue segment, decellularised, with a functional valve perfused with autologous peripheral blood
  • Sponsor:VeriGraft AB

Systemic scleroderma+1

Recruiting

A study to evaluate the safety and effectiveness of QEL-005 in patients with diffuse cutaneous systemic sclerosis and difficult to treat rheumatoid arthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:Quell Therapeutics Limited

Efficacy and safety of gadopiclenol versus gadoteric acid‑enhanced MRA in adult patients with suspected vascular disease

Recruiting
Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Gadoteric Acid

Vascular malformation

Recruiting

A study to evaluate the effectiveness of bleomycin sulfate for treating patients with low-flow vascular malformations using electrosclerotherapy.

Registered drugNo placebo
Countries:SloveniaSlovenia
  • Participants:18–64 years · 65+ years
  • Substances:Bleomycin Sulfate Ph. Eur.
  • Sponsor:Institute Of Oncology Ljubljana

Diabetic retinopathy+1

Recruiting

A study to evaluate the safety and effectiveness of ANXV in patients with diabetic retinopathy or retinal vein occlusion

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:ANXV
  • Sponsor:Annexin Pharmaceuticals AB (publ)

Diabetic foot

Recruiting

Evaluating the effect of semaglutide on wound healing in patients with diabetic foot ulcers

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Stichting Radboud universitair medisch centrum

Dementia+3

Recruiting

Using [18F]DED PET imaging to study brain changes in patients with Alzheimer's disease, CADASIL, and other forms of dementia.

InvestigationalNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:[18F]DED
  • Sponsor:Barcelonabeta Brain Research Center

Cardiovascular disorder+2

Recruiting

A study to compare the effects of BI 690517 and spironolactone on kidney function in patients with heart failure, cardiovascular disease, or chronic kidney disease

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Universitair Medisch Centrum Groningen

Substances studied in this area

The therapies tested most often in Vascular disorders trials.

Acetylsalicylic Acid59 clinical trialsSodium Chloride55 clinical trialsClopidogrel33 clinical trialsApixaban28 clinical trialsTicagrelor28 clinical trialsRivaroxaban21 clinical trialsAtorvastatin17 clinical trialsPrasugrel17 clinical trialsRituximab16 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.